---
title: "4D Molecular Therapeutics Q2 FY26 net loss widens to $72.94 million; revenue rises to $3.78 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295839631.md"
description: "4D Molecular Therapeutics reported a widened Q2 FY26 net loss of $72.94 million, up from $54.66 million year-ago, while revenue surged to $3.78 million due to Otsuka clinical-trial cost sharing. R&D expenses rose to $68.28 million for 4D-150 Phase 3 trials in wet AMD. Cash reserves stood at $430.63 million, supporting operations into H2 2028. Topline data for 4FRONT-1 and 4FRONT-2 are expected in 2027."
datetime: "2026-08-13T20:12:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295839631.md)
  - [en](https://longbridge.com/en/news/295839631.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295839631.md)
generator: "portal-rs"
---

# 4D Molecular Therapeutics Q2 FY26 net loss widens to $72.94 million; revenue rises to $3.78 million

-   4D Molecular Therapeutics posted a Q2 2026 net loss of USD 72.94 million, widening from USD 54.66 million a year earlier. \* Revenue rose to USD 3.78 million from USD 15,000, driven by Otsuka clinical-trial cost sharing and reimbursements. \* R&D expense climbed to USD 68.28 million from USD 47.95 million, reflecting execution of 4D-150 Phase 3 trials in wet AMD. \* Cash, cash equivalents, marketable securities totaled USD 430.63 million at June 30, down from USD 514.03 million at year-end 2025; runway seen into H2 2028. \* 4D-150 4FRONT-1 topline data expected in Q2 2027; 4FRONT-2 topline data expected in H2 2027, with a DME Phase 3 start targeted for Q3 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131605PRIMZONEFULLFEED9809218) on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [FDMT.US](https://longbridge.com/en/quote/FDMT.US.md)
- [4578.JP](https://longbridge.com/en/quote/4578.JP.md)

## Related News & Research

- [4D Molecular Therapeutics CEO David Kirn disposes of common shares worth $1,068,651.63](https://longbridge.com/en/news/296648682.md)
- [4D Molecular Therapeutics posts corporate presentation highlighting AAV gene therapy pipeline led by 4D-150 for wet AMD, DME](https://longbridge.com/en/news/296635019.md)
- [Apple declares Q3 2026 distribution of R$ 0.05 per unit, payable Aug. 19](https://longbridge.com/en/news/296137926.md)
- [Kreditbanken posts 2026 half-year report release](https://longbridge.com/en/news/296349936.md)
- [Public Storage announces R$ 0.41 per unit dividend for Q3 2026](https://longbridge.com/en/news/296635332.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**